This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the HeartRhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. EDT, in Rhythm Theater #2.
During its Annual Conference, HRS 2024, the HeartRhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF).
milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heartrhythms such as atrial fibrillation (AFib).
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrial fibrillation (A-Fib). This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients.
milla1cf Tue, 06/11/2024 - 18:09 June 11, 2024 — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.
An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany. Image courtesy: European Society of Cardiology.
milla1cf Tue, 05/21/2024 - 08:00 May 21, 2024 — Stereotaxis , a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to present at HRS Africa Summit 2024 , scheduled to take place during HeartRhythm Society Scientific Sessions in Boston, Massachusetts.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
milla1cf Thu, 05/30/2024 - 10:31 May 30, 2024 — Stereotaxis , a pioneer in surgical robotics for minimally invasive endovascular intervention, announced the successful treatment of the first heartrhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System.
Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.
The combined solutions are expected to enhance performance and streamline workflows for electrophysiologists during catheter ablation procedures to treat atrial fibrillation , AFib. Our mission to combat complex heartrhythm diseases relies on optimizing interoperability. The company has obtained U.S.
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrial fibrillation (A-Fib). This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients.
The robotic technology represented an entirely novel way to address heartrhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.
18, 2024 — The HeartRhythm Society (HRS) Board of Trustees unanimously approved the formation of HeartRhythm Advocates , a new, shared vision, cause-related nonprofit 501(c)(4) advocacy organization to complement the primary 501(c)(3) nonprofit structure of the HRS. tim.hodson Mon, 10/21/2024 - 11:24 Oct.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). iii] The study reported a low fluoroscopy time of 7.8
Understanding Atrial Fibrillation Atrial Fibrillation is characterized by an irregular and often rapid heartrhythm that can lead to poor blood flow. It occurs when the heart's upper chambers (atria) beat out of sync with the lower chambers (ventricles).
Additionally, this platform integrates parameters such as contact force measurement and ablation indexes for RF and PFA which have proven in preclinical studies to be critical for lesion creation. With this differentiated system, Biosense Webster is giving EPs the tools and information they need in real-time.
Understanding Atrial Fibrillation Atrial Fibrillation is characterized by an irregular and often rapid heartrhythm that can lead to poor blood flow. It occurs when the heart's upper chambers (atria) beat out of sync with the lower chambers (ventricles).
Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? Session 104) - What Is Really New in Electrophysiology That Will Change My Practice? 24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content